Premium
A Paclitaxel‐Based Mucoadhesive Nanogel with Multivalent Interactions for Cervical Cancer Therapy
Author(s) -
Qian Qiuhui,
Shi Leilei,
Gao Xihui,
Ma Yuan,
Yang Jiapei,
Zhang Zhihao,
Qian Jiwen,
Zhu Xinyuan
Publication year - 2019
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201903208
Subject(s) - nanogel , paclitaxel , drug delivery , in vivo , mucoadhesion , hela , drug carrier , chemistry , pharmacology , materials science , chemotherapy , in vitro , nanotechnology , medicine , surgery , biology , biochemistry , microbiology and biotechnology
Cervical cancer treatment is subject to limited drug access to locally diseased targets and generally resistant to chemotherapy, thus it is essential to develop a local drug delivery system to overcome these problems, premised on guaranteeing drug efficacy. With this goal in mind, a multivalent interactions‐based mucoadhesive nanogel for vaginal delivery is proposed. Briefly, the nanogel is constructed with mucoadhesive poly(acrylic acid) as the backbone and multiple inclusions between β‐cyclodextrin and paclitaxel as the crosslinking points. The in vitro experiments demonstrate that nanogel exerts high cytotoxicity to cancer cells, reverses multidrug resistance effectively, and successfully promotes the permeation of drugs. More to the point, as proved in the in vivo experiments, the retention time in the vagina is prolonged and the tumor growth is effectively suppressed by the nanogel without any side effects in the orthotopic cervical cancer model. As mentioned above, this novel mucoadhesive nanogel is believed to be a useful tool toward designing drug delivery systems for cervical cancer treatment.